Coco 2012.

Methods	Study design: parallel RCT Duration of study: 2002 to 2006 Duration of follow‐up: 12 months
Participants	Country: USA Setting: single centre Inclusion criteria: adult kidney transplant recipients Number: treatment group (20); control group (22) Mean age ± SD (years): treatment group (42 ± 11); control group (48 ± 14) Sex (M/F): treatment group (11/9); control group (16/6) Exclusion criteria: inability to return for regular follow‐up; participation in another study
Interventions	Treatment group Risedronate (oral): 35 mg weekly starting once SCr < 177 μmol/L Control group Placebo Co‐interventions Calcitriol: 0.25 μg daily
Outcomes	Change in BMD of lumbar spine, total hip and distal radius Bone fracture at any site Biomarkers of bone turnover Bone histomorphometry on bone biopsy
Notes	Funding source: quote "This study was supported by grants from the Kidney and Urology Foundation of America and the Institute for Clinical and Translational Research of Albert Einstein College of Medicine." Trial registration: NCT00266708
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated sequence
Allocation concealment (selection bias)	Unclear risk	Randomisation was done by pharmacist using computer‐generated randomisation. Reported in insufficient detail to perform adjudication
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical placebo achieved by over encapsulation of the risedronate capsules to appear similar to the placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	13/42 participants were not included in entire follow up for reasons that may have been related to outcome
Selective reporting (reporting bias)	High risk	Patient‐centred outcomes were not systematically evaluated or reported
Other bias	Low risk	Study appears free of other biases